Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
@ncar16
we had good news today and waiting for RNS to get it to confirm
For anybody who wants some more information about MGC
*********************************
Watch the MGC Pharma #MXC? webinar hosted by Vox Markets & Turner Pope Investments
https://youtu.be/qikchrfhkho
************************************
MGC Pharma's new head of global sales has big ambitions and says they're 'ready to go'
https://youtu.be/atRbVcHOyeY
***********************************
MGC Pharma – Edison Open House interview
https://youtu.be/itKwpRlACB0
***********************************
MGC Pharma reports 100% success rate in its phase II ArtemiC study in COVID-19
https://youtu.be/04dKV8oDIqU
a European based biopharma company specialising in the production and development of phytocannabinoid-derived
medicines is pleased to announce it has appointed highly experienced sales director, Nicole
Godresse, as its new Global Chief Sales Officer, effective immediately.
At MGC Pharma, Nicole will lead the Company’s global sales and marketing initiatives across
Australia and New Zealand as well as build and implement a strong and focused pharma sales
strategy by recruiting a highly experienced sales force around the world.
The new strategy will be rolled out following the completion of the integration of the recently
acquired Medicinal Cannabis Clinics (Refer ASX release 23 November 2020) and the Board is
confident it will deliver strong commercial results taking the Company through to its next phase of
growth, as an Australian market leader.
*****************************************
Nicole has over 20 years’ experience in the pharmaceutical/healthcare industry, holding
senior commercial roles with major multi-national companies including Eli Lilly, Johnson & Johnson,
Schering-Plough, Merck Sharp & Dohme, and most recently Tilray. Nicole is a true pioneer of
medicinal cannabis in Australia, New Zealand, and the broader Asia-Pacific region. In her most recent
roles as General Manager ANZ and Director of Emerging Markets at Tilray, Nicole was Instrumental
in launching the first Medical Cannabis brand legally in both Australia and New Zealand, launching
one of the first Medical Cannabis clinics in Australia, delivering some of Australia's first government-funded cannabis clinical trials, negotiating major exclusive government supply agreements, and
ultimately establishing a sustained market leadership position in both markets during her tenure.
Nicole also made significant inroads into Asia including negotiating the supply of CBD product
imports into the region. Through these roles, Nicole has developed not only exceptional market
knowledge and expertise but also built a strong network of government, industry, and customer
stakeholders globally.
Nicole will report to Managing Director, Roby Zomer and her remuneration package will include a
base salary of $96,000 per annum, together with a performance-focused equity incentive structure
contingent on the delivery of key sales and revenues milestones, including the delivery of $1million in
revenue per month in 2021
for the people who compare MGC with Vape company ( Kanabo ). Read above
I did add this to the yahoo MGC conversation earlier. now everybody going to jump in.
Goddam I think, I just move the price with this news. lol
@Bushmaster
Thanks mate.
I believe we will get a nice big juicy RNS soon
Relay Medical Reports Glow LifeTech Secures Exclusive North American Rights to ArtemiC(TM) Following Successful COVID-19 Phase II Clinical Trial
Toronto, Ontario--(Newsfile Corp. - February 16, 2021) - Relay Medical Corp. (CSE: RELA) (OTCQB: RYMDF) (FSE: EIY2) ("Relay" or the "Company"), a technology developer and innovator, and Glow LifeTech Ltd. ("Glow"), a private company in which Relay holds a significant equity interest, are pleased to report that Glow has executed an agreement with Swiss Pharmacan AG ("the agreement") for exclusive North American and Carribean sales and distribution rights for ArtemiC™ , a natural health product based on Glow's MyCell™ Technology ("MyCell") which recently reported successful results from a COVID-19 Phase II clinical trial (see Relay's release dated Jan 14, 2021).
Under the terms of the agreement, signed on February 16, 2021, Glow has exclusive rights to market, sell and distribute ArtemiC™ in Canada, U.S., Mexico and all Carribean countries as a food supplement. ArtemiC™ is a clinically tested food supplement (nutraceutical, dietary supplement, natural health product) containing four natural based ingredients consisting of Artemisinin, Curcumin, Boswellia serrata, and Vitamin C. The formulation uses Glow's MyCell™ delivery system technology to increase bioavailability and effectiveness of natural active ingredients. ArtemiC™ was a collaborative development effort with Glow's strategic partner, Swiss PharmaCan AG and MGC Pharma ("MGC"), and will be manufactured by MGC Pharma under EU-GMP.
"This is a significant new product opportunity for Glow and our shareholders, as ArtemiC™ shows promising results that it may improve the clinical recovery of COVID-19 patients," said Rob Carducci, Chief Commercial Officer, Glow LifeTech Ltd. "We are extremely pleased that our MyCell™ Technology is helping to power a natural, safe and effective product that can be made widely accessible during these challenging times."
Recently, MGC announced the results of a Phase II double-blind, placebo-controlled clinical trial, which showed ArtemiC™ statistically significantly improved the clinical recovery of COVID-19 patients in comparison with the Placebo Group[1]. 100% of the patients in the treatment group met the trial's primary endpoint and fully recovered within 15 days. None of the patients supported by ArtemiC™ required additional oxygen, mechanical ventilation or intensive care, compared to 23.4% in the placebo group requiring further assistance. The results deliver a full safety and efficacy profile, which is further supported by additional testing done by MGC on toxicity and mechanism of action.
https://www.newsfilecorp.com/release/74643/Relay-Medical-Reports-Glow-LifeTech-Secures-Exclusive-North-American-Rights-to-ArtemiCTM-Following-Successful-COVID19-Phase-II-Clinical-Trial
I'm agreed and for the people, who are confused about the recent RNS which I believe was very good news for the UK shareholders please read this explanation.
***************
What is a Depositary Interest (DI)?
A DI is a legal wrapper which, when placed around non-UK shares, converts them to CREST-eligible UK securities. The service is provided by a registrar, with the shares held in custody on the share register and converted to a UK DI through a Trust Deed Poll. The company is then able to list its shares for trading on the London markets, with the DIs settling those trades electronically within CREST.
DIs are distinct from Global Depositary Receipts (GDRs). With DIs, the shares themselves are listed on an overseas exchange and the DIs are used to settle trades in London. They are suitable for single or dual-listed companies, who are seeking both institutional and retail investors. GDRs, in contrast, are securities in their own right and are listed, traded, and settled. They are suited to dual-listed companies who want access to institutional investors.
There is also an important legal requirement for a DI, namely the recognition of trust in the territory where the company is incorporated. In practice, this means that companies in countries with a common law system (primarily the Commonwealth), or with a mixed common and civil law system, will find it significantly easier and faster to create a DI.
The benefits of DIs
DIs offer significant benefits to issuers, investors, and brokers.
Issuers
The primary benefit for issuers is access to capital raising in London and the increased liquidity this brings. Issuers receive a fully sponsored program, including a general meeting and voting service, multi-currency dividend payments, and support for corporate actions. Issuers also particularly value having visibility of their investors and the ability to communicate directly with them.
Investors
DIs offer investors local access to foreign investment, with market trades settled electronically. DIs are created and canceled on-demand and give investors the same rights and entitlements as direct shareholders, including the ability to attend meetings and receive dividends and communications from the issuer.
Brokers
In many respects, DIs represents business as usual for brokers. Trades in foreign companies can be settled locally, through the same CREST system that brokers are used to. Brokers also gain access to multiple markets and benefit from the full voting and dividend service.
All my buy orders are pending!!!!!
I hope this will helpful:
What is a Depositary Interest (DI)?
A DI is a legal wrapper which, when placed around non-UK shares, converts them to CREST eligible UK securities. The service is provided by a registrar, with the shares held in custody on the share register and converted to a UK DI through a Trust Deed Poll. The company is then able to list its shares for trading on the London markets, with the DIs settling those trades electronically within CREST.
DIs are distinct from Global Depositary Receipts (GDRs). With DIs, the shares themselves are listed on an overseas exchange and the DIs are used to settle trades in London. They are suitable for single or dual-listed companies, who are seeking both institutional and retail investors. GDRs, in contrast, are securities in their own right and are listed, traded and settled. They are suited to dual-listed companies who want access to institutional investors.
There is also an important legal requirement for a DI, namely the recognition of trust in the territory where the company is incorporated. In practice, this means that companies in countries with a common law system (primarily the Commonwealth), or with a mixed common and civil law system, will find it significantly easier and faster to create a DI.
The benefits of DIs
DIs offer significant benefits to issuers, investors and brokers.
Issuers
The primary benefit for issuers is access to capital raising in London and the increased liquidity this brings. Issuers receive a fully sponsored programme, including a general meeting and voting service, multi-currency dividend payments and support for corporate actions. Issuers also particularly value having visibility of their investors and the ability to communicate directly with them.
Investors
DIs offer investors local access to foreign investment, with market trades settled electronically. DIs are created and cancelled on demand and give investors the same rights and entitlements as direct shareholders, including the ability to attend meetings and receive dividends and communications from the issuer.
Brokers
In many respects, DIs represent business as usual for brokers. Trades in foreign companies can be settled locally, through the same CREST system that brokers are used to. Brokers also gain access to multiple markets and benefit from the full voting and dividend service.
@Bushy100,
you are right. that RNS is nothing to do with the UK shares its only effect Australian shareholder not in the bad way but I think the people panic about it. MGC wants LSE to be the main market for them I believe.
MGC Pharmaceuticals Limited (ASX, LSE: MXC) (MGC, or the Company), is pleased to present the following information to investors regarding the Company's Depositary Interest (DI) facility which will enable MGC Pharma Shares to be tradable on the London Stock Exchange (LSE).
Admission and trading in MGC Pharma Shares on the London Stock Exchange (LSE) commenced on 8.00am GMT on Tuesday 9 February 2021 under the ticker "LSE: MXC". MGC Pharma retains its existing primary listing on the Australian Securities Exchange (ASX) where it will continue to trade as normal under the ticker "ASX: MXC".
Admission and trading in MGC Pharma Shares on the London Stock Exchange (LSE) commenced at 8.00 am GMT on Tuesday 9 February 2021 under the ticker "LSE: MXC". MGC Pharma retains its existing primary listing on the Australian Securities Exchange (ASX) where it will continue to trade as normal under the ticker "ASX: MXC".
I think it went down in Australia because of the Rns we had yesterday.
I don't know why people talking about different stocks on here?
1. CannEpil® is a Phytocannabinoid derived IMP used as a treatment for refractory epilepsy
* Available to prescribe in Australia and UK as an Investigational Medicinal Product through early patient access schemes
*Estimated yearly average treatment costs per patient: A$10,000 – A$14,000
Target Market:
• Over 1,900,000 people have epilepsy in Europe (over 480,000 epilepsy patients in the UK)
• Over 200,000 epilepsy patients in Australia
• Approximately 25% of people with epilepsy have a drug-resistant (DRA) form
• Estimated population at the launch of marketing authorization is over 200,000 people with DRA (in Europe and Australia)
• Expected time to marketing authorization 4 years
The global epilepsy market is expected to be ~A$12.9bn by 2023
************************
2.CogniCann® is MGC Pharma’s second Phytocannabinoid derived IMP designed to improve dementia and Alzheimer’s disease patients quality of life
*Available to prescribe in Australia as an Investigational Medicinal Product through Early Patient Access Scheme
*Estimated yearly average treatment costs per patient: A$7,800
Target Market:
• Over 690,000 people with mild dementia in Europe (over 200,000 mild dementia patients in the UK)
• Over 135,000 mild dementia patients in Australia
• Total estimated with mild dementia population 950,000 at marketing authorization launch (in Europe and Australia)
• Expected time to marketing authorization 5 years
The global dementia medication market is expected to exceed ~A$40bn by 2026
******************************
ArtemiCTM is a natural water-soluble food supplement containing four natural based ingredients consisting of Artemisinin,
Curcumin, Boswellia serrata, and Vitamin C
• ArtemiCTM uses the MyCell EnhancedTM delivery system technology, a patented platform to deliver natural
ingredients more effectively in higher concentrations to the cells, improving the bioavailability of natural ingredients
• The Phase II human clinical trial testing ArtemiCTM for treatment of COVID-19 included 50 patients across three
hospital sites, Nazareth Hospital EMMS, Hillel Yaffe Hospital in Israel, and Mahatma Gandhi Mission’s Medical
College & Hospital in India
• 33 Patients were in the treatment group and 17 patients were in the placebo group
• ArtemiCTM successfully met all its primary and secondary study endpoints (100% of patients in the treatment
group), and all FDA requirements for the diversity of patients
• ArtemiCTM delivered a NEWS score (main parameter of clinical improvement in COVID-19 patients) of less than or
equal to 2 in 100% of patients in the treatment group
• None of the patients in the treatment group required additional oxygen, mechanical ventilation, or admission to
intensive care
• Results also deliver a full safety and efficacy profile, demonstrating to improve and expedite the clinical recovery in
moderate COVID-19 patients
HAVE A NICE DAY
MGC Pharmaceuticals Ltd (ASX: MXC) (OTCMKTS: MGCLF) plans to pursue its new growth strategy this year and is confident it will continue its trajectory of delivering strong commercial results.
Late last year, the company announced it would be the recipient of a 3.1 million Euro (~A$5 million) cash grant to set up a fully functional GMP certified facility in Malta to produce a COVID-19 anti-inflammatory product ArtemiC™ in liquid dose form.
The grant from Malta Enterprise will enable the company to renovate and extend its existing Clinical Research Organisation (CRO) facility in Malta.
This will create a European manufacturing hub for ArtemiC™ with the ability to scale production to meet expected growing demand following positive clinical trial results.
The European Union GMP-compliant facility will be able to produce 10,000 units of liquid dose medicines per day.
European manufacturing hub
The company has received strong support from the Maltese government through Malta Enterprise to establish the world-class GMP facility to respond to the growing pharma and cannabis industries on the island.
Construction of the extension to the MXC Malta facility has commenced and is expected to be completed in the second quarter of 2021.
Upon completion of the facility, MGC Pharma will be in a strong position to streamline global distribution via Malta’s convenient shipping access to the entire globe.
Initial target markets for the distribution of ArtemiC™ will be Israel, Russia, the CIS countries, and countries in the Balkan region as determined by a distribution agreement signed with KS Kim International, a wholly-owned subsidiary of SK-Pharma group.
ArtemiC™ strong clinical trial results
In December, the company’s Phase II double-blind, placebo-controlled clinical trial for ArtemiC™ on those diagnosed with COVID-19 met all the Phase II primary and secondary endpoints and was demonstrated to improve the clinical recovery of the patients.
This Phase II trial involved 50 infected patients across three independent hospital sites in Israel and India, with 33 in the treatment group and 17 in the placebo group.
The full results have demonstrated to improve the health status of COVID-19 patients with none of the patients in the treatment group required additional oxygen, mechanical ventilation, or admission to intensive care where all of these events were reported in the placebo group.
Further development for ArtemiC™ will include immediate evaluation of a Phase III clinical study on COVID-19 and flu patients, and production in the company’s EU GMP facilities, as IMP under a new brand name.
Different indications related to inflammation and cytokine storm will be considered as future development goals and include a wide range of diseases related to cytokine storms such as autoimmune diseases, inflammatory GI diseases, flu, and chemotherapy patients.
The company plans to develop and commence a Phase III Clinical Trial in the first half of 2021.
I think we need to compare MGC with GWP.
GWP Development Pipeline:
CBDV (GWP42006)
1. This is a homologue of cannabidiol currently being developed for the treatment of epilepsy and autism spectrum disorders. It has a very slightly different chemical structure to the original molecule but has been shown to posses similar properties. It is also a non-psychoactive cannabinoid. It is currently in the initial stages of development, but has so far shown promising results. ( Epilepsy / Autism Spectrum Disorders both are in phase 2)
2. In addition, we have a number of other products at various stages in the development pipeline. These include GWP42003 IV for Neonatal Hypoxic-Ischemic Encephalopathy, GWP42002/GWP42003 for Glioblastoma, and GWP42003 for Schizophrenia. ( Neonatal Hypoxic-Ischemic Encephalopathy / Glioblastoma / Schizophrenia )
*********************
MGC Development Pipeline:
1. CANNEPIL® – DESIGNED FOR TREATMENT OF REFRACTORY EPILEPSY
Phase IIb Clinical Trial at Schneider Hospital in Israel on the safety and efficacy of CannEpil® as an add on treatment in children and adolescents with refractory epilepsy
A controlled trial with the Swinburne University of Technology, Melbourne to assess the effect of CannEpil® on driving performance
2. COGNICANN® - DESIGNED FOR TREATMENT OF DEMENTIA AND ALZHEIMER’S DISEASE
Phase II Clinical Trial with the University of Notre Dame in Perth, WA to evaluate the potential behavioral benefits CogniCann®may have on patients with dementia and Alzheimer’s disease
3. ARTEMIC – DESIGNED FOR TREATMENT OF COVID-19
Phase II Clinical Trial on ArtemiC is designed to target viral infections with inflammatory complications, and currently, the safety and efficacy are being evaluated on COVID-19 infected patients. Trials are currently being undertaken at Nazareth Hospital EMMS and Hillel Yaffe Hospital in Israel, and Mahatma Gandhi Mission’s Medical College & Hospital, India
**********************
So if we look at these pipelines for these 2 companies, we can see they are not the same as other cannabis companies such as Canabo, Aphria, Aurora which they making CBD oil for vape.
Some more info for LTH research:
***********************
Key Highlights:
• Strong quarter delivered with global MGC Pharma product sales generating revenue of
$456,000 from 2,900 units of products sold. This represents an increase of 67% growth from
the previous quarter.
• Significant operational and commercial progress delivered across all pharma operations
pushing the Company towards its goal of achieving monthly cashflow breakeven by end 1H
2021 from ~ 5,000 units sold per month.
• ArtemiCTM Phase II Clinical Trial completes and delivers excellent results by meeting all
primary and secondary endpoints.
• $5 million (€3.1 million), non-dilutive cash grant secured and funding commenced from Malta
Enterprise to finance over 80% a fully certified GMP facility in Malta, for the production of
ArtemiCTM – construction materially advanced, provide large scale production capacity for
ArtemiCTM .
• Acquisition of Medicinal Cannabis Clinics completed, with over 300 patient consults
conducted since completion on the 23rd of November. Alongside the increased revenue
generated from consults, the acquisition brings distribution that provides higher import and
export capacity with significantly higher profit margins while maintaining a competitive product
prices.
• Results from an ongoing study into the treatment of glioblastoma show MXC’s proprietary
formulation, CBG, impairs the major hallmarks of glioblastoma progression.
• Launch of CannEpil® app which provides access to the international library of Cannabinoids as
part of its ongoing research with RMIT.
• The sale of MGC Nutraceuticals significantly advanced as both the Company and Onassis have
submitted the required documentation to the US SEC.
• Material progress towards strategic dual listing on the London Stock Exchange, following
release of regulatory guidance notes for cannabis companies in September 2020 – no cannabis
companies currently listed on the main stock exchanges in the United Kingdom.
******************